Results 251 to 260 of about 325,932 (347)

Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia. [PDF]

BMC Infect Dis
Yunihastuti E, Nugroho P, Yusuf M, Lastari SD, Harinda F, Putri TK, Pane MR, Pratama MA, Yulianti M, Widhani A, Maria S, Hasibuan AS, Marbun MBH, Koesnoe S, Karjadi TH.   +14 more
europepmc   +1 more source

Estimated glomerular filtration rate

, 2019
Daniel Bell, Rohit Sharma, Ben Chan
openaire   +1 more source

Glomerular filtration rate and comorbidity factors in elderly hospitalizations. [PDF]

World J Nephrol
Hamarat H.
europepmc   +1 more source

Estimated Glomerular Filtration Rate [PDF]

, 2020
openaire   +1 more source

MON-524 Risk of Decline in Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hypoparathyroidism (HypoPT)

, 2019
Kristina Chen, Gary C. Curhan, Elvira O. Gosmanova, Lars Rejnmark, Elyse Swallow, Allison Briggs, Monica Macheca, Nicole Sherry, Markus Ketteler   +8 more
openalex   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

CT-free kidney single-photon emission computed tomography for glomerular filtration rate. [PDF]

Sci Rep
Kwon K, Oh D, Kim JH, Yoo J, Lee WW.
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Beyond Function: Did Anesthetic Choice Influence Subclinical Kidney Injury Rather Than Estimated Glomerular Filtration Rate? [Letter]. [PDF]

Drug Des Devel Ther
Chen YJ, Tai WH, Hung MH.
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source